Research status on immunotherapy-related hyperprogression for head and neck squamous cell carcinoma

VernacularTitle:头颈鳞癌免疫治疗超进展的研究现状
Author: Huang QIUYI ¹ ; Xu LINGFENG ¹ ; Fan QIANYU ¹ ; Chen JIAN ¹
Author Information

1. 华中科技大学同济医学院附属肿瘤医院头颈外科武汉市430079
Publication Type:Journal Article
Keywords: head and neck squamous cell carcinoma (HNSCC); immunotherapy; immune checkpoint inhibitors (ICIs); hyperprogressive disease (HPD)
From: Chinese Journal of Clinical Oncology 2024;51(21):1125-1130
CountryChina
Language:Chinese
Abstract: Head and neck squamous cell carcinoma (HNSCC) is a highly invasive malignant tumor. Although patients receive standard treat-ment,the risk of local recurrence and distant metastasis remains high,resulting in a poor prognosis. In recent years,immune checkpoint in-hibitors (ICIs) have shown significant efficacy in the treatment of a variety of solid tumors and have changed the treatment modality for many advanced tumors. However,in some patients,immunotherapy not only failed to bring survival benefits but also led to the rapid growth of tumor lesions in a short period of time,which is clinically known as hyperprogressive disease (HPD). There is limited research on the mechanism,clinical predictors,and coping strategies for immunotherapy-related hyperprogression. Therefore,this article focuses on HNSCC and reviews the current research on HPD to provide a scientific basis for optimizing immunotherapy.